Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × pertuzumab × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 152 HER2-positive Breast Cancer 15 Neoplasm Metastasis 5 Neoplasms 4 Inflammatory Breast Neoplasms 4 Triple Negative Breast Neoplasms 3 Pathologic Complete Response 3 HER2-positive Early Breast Cancer 3 Breast Neoplasms, Male 3 Anatomic Stage I Breast Cancer AJCC v8 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Locally Advanced Breast Cancer 2 HER2-positive Metastatic Breast Cancer 2 Gastrointestinal Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Ductal, Breast 2 Brain Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Thrombocytosis 1 Stomach Neoplasms 1 Sarcoma 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Patient Preference 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡